BNR · Burning Rock Biotech Ltd
Market Cap
$199.75M
Shares
10.55M
Volume · Oct 5
49.06K
Avg daily vol (3M)
30.01K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$16.25
Open$16.36
Day$16.05–16.79
52W close$7.04–41.06
Avg vol 30d50K
Short int39K · 0.4% float · 1.0d
Short vol72%
Last earningsMar 29, 2024
DataJun 2020–Oct 2026
Up next
call held Mar 29, 2024
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
+80.4%
Trailing year
Short interest
0.4%
Latest settlement · 1.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Neutral
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.5 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−6%
below
Price vs 50-day avg
+41%
above
RSI (14)
58
neutral
MACD trend
Positive
52-week position
27%
mid-range
Volume (OBV)
Bearish div.
distributing
Momentum
relative strength
1-month return
+51%
trailing
6-month return
+3%
trailing
YTD return
−19%
this year
Relative strength
−10%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $12 › 200d $17 — 200d above 50d
Institutional flow
Accumulating
+6% holders QoQ · +3 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.37% of float · ▲ +3.2% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
17 holders — mid 3-yr range
Squeeze score
52
elevated · 0–100
Fundamentals
Revenue growth
+9%
Y/Y
Gross margin
75%
expanding
Free cash flow
$-4.8M
Buyback
$10.0M
authorized
Quant / Vol
risk profile
Volatility
129%
annualized · 1-yr
Max drawdown
−83%
past year
ATR
9.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−6%
Bearish
Price vs 50-day avg
+41%
Bullish
RSI (14)
58
Neutral
MACD trend
Positive
Bullish
52-week position
27%
Neutral
Volume (OBV)
Bearish div.
Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $12 › 200d $17 — 200d above 50d
Institutional flow
Accumulating
+6% holders QoQ · +3 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.37% of float · ▲ +3.2% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
17 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $7
Now $16 · 27%
Range high $41
vs 200-day avg -6%
vs 50-day avg +41%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BNR
this stock
Burning Rock Biotech Ltd
|
$199.75M | -19.4% | +9.2% | — | 0.4% |
|
TMO
Thermo Fisher Scientific Inc.
|
$249.58B | +13.0% | +14.5% | 36.3 | 1.4% |
|
DHR
Danaher Corp /De/
|
$150.37B | -6.5% | +8.5% | 37.9 | 1.2% |
|
NTRA
Natera, Inc.
|
$59.47B | +79.1% | -2.8% | — | 3.3% |
|
A
Agilent Technologies, Inc.
|
$48.90B | +23.3% | +6.4% | 34.2 | 1.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BNR | -12.6% | +50.7% | +2.6% | -7.8% | -19.4% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -12.4% | +51.2% | -9.6% | -8.8% | -32.2% |
Capital returns
Buyback program
· as of Jun 30, 2022
Authorized
$10.00M
Spent (derived)
—
Remaining
—
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.